Skip to content

Effects of a Multidisciplinary Outpatient Rehabilitation Program in Patients With Ehlers-Danlos Syndrome.

Effects of a Multidisciplinary Outpatient Rehabilitation Program on Physical Capacity and Quality of Life in Patients With Ehlers-Danlos Syndrome.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04680793
Enrollment
25
Registered
2020-12-23
Start date
2020-09-22
Completion date
2022-04-13
Last updated
2022-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ehlers-Danlos Syndrome

Keywords

Rehabilitation; Ehlers-Danlos syndrome; Quality of life; Physical capacity

Brief summary

The management of patients with Ehlers-Danlos syndrome (EDS) is still underdeveloped in healthcare institutions in France. Although multidisciplinary management through exercise rehabilitation has demonstrated its benefits in many chronic pathologies, it has not been evaluated for EDS. As a result, to date there is no evidence of its effectiveness in patients with EDS. The objective of this study is therefore to objectively evaluate the effectiveness of such a treatment on the different dimensions of these patients' health.

Interventions

OTHERRehabilitation

The program takes place over a total period of 9 weeks: for 4 weeks they will be cared for two days a week, then after a week's break, for 4 weeks they will be cared for three days a week for a total of approximately 80 hours of care. The program is multidisciplinary and includes: balneotherapy, ergometry, occupational therapy, gymnastics, physiotherapy, walking, sophrology, yoga as well as different workshops for the therapeutic education of the patient led by several professionals (dieticians, physiotherapists, doctors, psychologists).

Sponsors

Hakimi Adrien
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Patients are assessed 9 weeks before the start of the program, at the beginning and at the end of the program, and 6 weeks and 6 months after the end of the program. The 9-week period before the program is used as a control condition. It is of the same duration as the program, which also lasts 9 weeks. Patients are asked not to change their lifestyle during the 9-week period before the rehabilitation program.

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* EDS diagnosis. * Inclusion in the rehabilitation program.

Exclusion criteria

* Absolute and relative cardio-vascular contraindications to rehabilitation. * Other contraindications to exercise. * Psychological contraindication (Beck questionnaire score ≥ 20)

Design outcomes

Primary

MeasureTime frame
Distance covered in the 6-minute walk test9 weeks before baseline ; Baseline ; 9 weeks ; 15 weeks ; 8 months

Secondary

MeasureTime frameDescription
Time of an endurance test on a cyclo-ergometerBaseline ; 9 weeks
Area swept by the gravity center during a balance test on a posturological platform9 weeks before baseline ; Baseline ; 9 weeks ; 15 weeks ; 8 monthsFour balance tests : bipodal with eyes open, bipodal with eyes closed and unipodal with eyes open on the two sides
Tampa scale for kinesiophobia (questionnaire)9 weeks before baseline ; Baseline ; 9 weeks ; 15 weeks ; 8 months
Brief pain inventory (questionnaire)9 weeks before baseline ; Baseline ; 9 weeks ; 15 weeks ; 8 months
Other data from the 6-minute walk test9 weeks before baseline ; Baseline ; 9 weeks ; 15 weeks ; 8 months
Multidimensional fatigue inventory (questionnaire)9 weeks before baseline ; Baseline ; 9 weeks ; 15 weeks ; 8 months
Medical outcome study short form 36 (questionnaire)9 weeks before baseline ; Baseline ; 9 weeks ; 15 weeks ; 8 months
Hospital anxiety and depression scale (questionnaire)9 weeks before baseline ; Baseline ; 9 weeks ; 15 weeks ; 8 months
Nijmegen questionnaire9 weeks before baseline ; Baseline ; 9 weeks ; 15 weeks ; 8 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026